Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT06863961
- Locations
- 🇺🇸
Goodlettsville Dermatology Research, Goodlettsville, Tennessee, United States
🇺🇸Reveal Research Institute, Dallas, Texas, United States
🇺🇸Dermatology Research Associate, Los Angeles, California, United States
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 800
- Registration Number
- NCT06862869
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Device: Susvimo PDS Implant
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 250
- Registration Number
- NCT06847542
A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Crohn's Disease
- Conditions
- Moderately to Severely Active Crohns Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 425
- Registration Number
- NCT06819891
- Locations
- 🇫🇷
Hopital Dupuytren, Limoges, France
🇫🇷Hopital Saint-Eloi, Montpellier, France
🇺🇸Om Research LLC, Lancaster, California, United States
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Participants With Moderately to Severely Active Crohn's Disease
- Conditions
- Moderately to Severely Active Crohns Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 600
- Registration Number
- NCT06819878
- Locations
- 🇺🇸
Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, Dothan, Alabama, United States
🇺🇸Arizona Digestive Health, P.C (ADH), Sun City, Arizona, United States
🇺🇸Valley View Internal Medicine, Garden Grove, California, United States
A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- Drug: BCG Medac Strain
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT06816017
- Locations
- 🇮🇹
A.O.U di Verona Policlinico G.B. Rossi, Verona, Veneto, Italy
🇲🇾Hospital Umum Sarawak, Kuching, Sarawak, Malaysia
🇦🇺Macquarie University Hospital, Macquarie Park, New South Wales, Australia
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT06806033
- Locations
- 🇫🇷
CHU DE RENNES - CHU Pontchaillou, Rennes, France
🇺🇸Alaska Oncology & Hematology, LLC, Anchorage, Alaska, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 274
- Registration Number
- NCT06795048
- Locations
- 🇺🇸
Retinal Vitreal Consultants, Chicago, Illinois, United States
🇺🇸New England Retina Consultants, Springfield, Massachusetts, United States
🇺🇸Retina Consultants of Texas, Schertz, Texas, United States
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung CancerKRAS G12C Lung Cancer
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 600
- Registration Number
- NCT06793215
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 450
- Registration Number
- NCT06790693
- Locations
- 🇹🇷
Ba?c?lar Medipol Mega Üniversite Hastanesi, Istanbul, Turkey
🇺🇸Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States
🇺🇸Springfield Clinic, Springfield, Illinois, United States